MGTX News and Press, MeiraGTx Holdings plc From 03/04/21

LONDON and NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barc...

AGTC leads the pack among Biogen, JNJ and MeiraGTx in developing gene therapies for certain eye diseases. Cash balance is decent. If successful, AGTC could see some upside from these levels. For further details see: Applied Genetic Technologies: Leader Among Larger Peers...

Today, we take our first look at a small gene therapy concern called MeiraGTx Holdings. The company has several compounds in development, has inked a large collaboration agreement, and has recently addressed its funding needs. Our in-depth research on this small-cap name follows i...

The FDA grants Fast Track designation to MeiraGTx Holdings' (MGTX) AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia ((ACHM)) caused by mutations in the CNGA3 gene.Fast Track status provides for more frequent interaction with the FDA review team and a rolling review ...

LONDON and NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its AAV-CNGA3 gene therapy product...

MGTX has early proof of concept data for ophthalmic rare disease indications using its gene therapies. It has inked two deals with Janssen, one of them quite lucrative. The company does not have a lot of cash, but its pipeline is interesting. For further details see: Mei...

LONDON and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will host a webcast and conference call to provide an update on the Company’s AAV-hAQP...

LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 3 ...

LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in a fir...

Shares of MeiraGTx Holdings (NASDAQ:MGTX) -- a clinical-stage biotech company -- are down by 11.51% as of 11:55 a.m. EST on Thursday, following the company's announcement of the pricing of a public offering of common stock. Investors aren't thrilled with the prospect of MeiraGTx dil...